# Cue Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cue-health

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Total disclosed funding: $155M
- Latest round: Series C (Jun 1, 2020)
- Investors on record: 15

## About

Based in California, US, and founded in 2010 by co-founder Ayub Khattak and Clint Sever, Cue Health Inc. operates as a developer and manufacturer of a connected medical diagnostic system. In October 2020, the company received a government grant of USD 481 million for the production of rapid COVID-19 molecular tests. In June 2020, the company was also granted an Emergency Use Authorization (EUA) from the US Foods and Drug Administration for the use of the Cue COVID-19 Test Cartridge in conjunction with the Cue Health Monitoring System. In September 2021, Cue Health was listed on the Nasdaq Global Market under the ticker symbol "HLTH". The company offers Cue Health Monitoring System which is a portable device linked to a diagnostic platform that performs molecular testing and transforms test samples into digital results. The device is used in conjunction with the Cue Test Cartridge, the Cue Sample Wand, and the Cue Health App. Cue Health also manufactures a COVID-19 Test Cartridge, a single-use, self-contained unit that uses technology to apply the chemicals and related materials needed for molecular detection of the SARS-CoV-2 virus.

## Funding rounds

- Series C, Jun 1, 2020, $103M — Johnson & Johnson Innovation, Madrone Capital Partners, Foresite Capital, Decheng Capital, ACME Capital
- Series B, Jul 10, 2018, $45M — Pritzker Group Venture Capital, Johnson & Johnson Innovation, Sherpa Capital, Synergy Ventures, ACME Capital, Tarsadia Investments, Dentsu Ventures, Section 32, Troy Capital Partners, BABEL Ventures, Cove Investment Partners
- Series A, Nov 18, 2014, $7.5M — ACME Capital, Immortalana

## Investors

- ACME Capital (https://capitalatlas.ai/funds/acme-capital) — Series A, Series B, Series C
- Immortalana (https://capitalatlas.ai/funds/immortalana) — Series A
- Pritzker Group Venture Capital (https://capitalatlas.ai/funds/pritzker-group-venture-capital) — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- Sherpa Capital (https://capitalatlas.ai/funds/sherpa-capital) — Series B
- Synergy Ventures (https://capitalatlas.ai/funds/synergy-ventures) — Series B
- Tarsadia Investments — Series B
- Dentsu Ventures (https://capitalatlas.ai/funds/dentsu-ventures) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Troy Capital Partners (https://capitalatlas.ai/funds/troy-capital-partners) — Series B
- BABEL Ventures (https://capitalatlas.ai/funds/babel-ventures) — Series B
- Cove Investment Partners — Series B
- Madrone Capital Partners — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C